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Modification of gene activity in mouse embryos in utero by a
tamoxifen-inducible form of Cre recombinase
Paul S. Danielian*†, David Muccino*, David H. Rowitch*‡, Simon K. Michael*§
and Andrew P. McMahon*
The ability to generate specific genetic modifications in
mice provides a powerful approach to assess gene
function. When genetic modifications have been
generated in the germ line, however, the resulting
phenotype often only reflects the first time a gene has
an influence on — or is necessary for — a particular
biological process. Therefore, systems allowing
conditional genetic modification have been developed
(for a review, see [1]); for example, inducible forms of
the Cre recombinase from P1 phage have been
generated that can catalyse intramolecular
recombination between target recognition sequences
(loxP sites) in response to ligand [2–5]. Here, we
assessed whether a tamoxifen-inducible form of Cre
recombinase (Cre–ERTM) could be used to modify gene
activity in the mouse embryo in utero. Using the
enhancer of the Wnt1 gene to restrict the expression of
Cre–ERTM to the embryonic neural tube, we found that a
single injection of tamoxifen into pregnant mice
induced Cre-mediated recombination within the
embryonic central nervous system, thereby activating
expression of a reporter gene. Induction was ligand
dependent, rapid and efficient. The results demonstrate
that tamoxifen-inducible recombination can be used to
effectively modify gene function in the mouse embryo.
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Results and discussion
We have developed a transgenic reporter system to deter-
mine whether an inducible form of Cre recombinase can
be used for recombination-mediated modulation of gene
activity in the developing mouse embryo. A construct that
could function as a reporter for Cre recombinase activity in
vivo was derived from the Wnt1-enhancer-based expres-
sion construct pWEXPZ2, which is active from 8.0 days
post coitum (dpc) in the neural plate of the mouse embryo
[6,7]. In brief, a cassette containing the neo gene under the
control of the promoter for phosphoglycerate kinase
(PGKneobpA) flanked by loxP sites was inserted just 5′ to
a lacZ reporter to prevent translation of lacZ mRNA until
Cre-mediated excision of the neo cassette (for details, see
Supplementary material published with this paper on the
internet). Transfected R1 embryonic stem (ES) cells were
used to generate mice. To determine whether the reporter
could be activated appropriately, zygotes from each line
were injected with a plasmid encoding Cre recombinase.
Recombination was initially scored using a PCR-based
assay and by staining for β-galactosidase activity. Two
lines, R170 (two copies of reporter) and R44 (three copies
of reporter) showed virtually no reporter activity prior to
recombination (Figure 1a). Following Cre expression in
the zygote, the neo cassette was excised and β-galacto-
sidase activity was detected in the Wnt1 expression
pattern, that is, initially in the midbrain (Figure 1b,c) and,
after neural tube closure, in the dorsal and ventral mid-
lines of the midbrain and caudal diencephalon, the mid-
brain–hindbrain junction and in the dorsal spinal cord
(Figure 1d). Although both reporter lines were tested in
all subsequent studies with equivalent results, R170
showed stronger expression and we focused on this line.
To express Cre within the Wnt1 expression domain, the
cDNA for Cre was placed under the control of the Wnt1
enhancer. Transgenic mouse strains that expressed this
construct were mated with the R170 reporter line to deter-
mine whether Cre-mediated activation of the reporter
could take place within the Wnt1 expression domain (Cre
function is restricted to the Wnt1 expression domain in
these lines; data not shown). In embryos carrying both
transgenes, β-galactosidase activity was always detected
within the midbrain by 8.5 dpc (n > 4; Figure 1e), and the
complete pattern of expression by 11.5 dpc (n > 10; Figure
1f). Thus, the reporter can be activated within the Wnt1
domain, and activation — which requires intragenic
recombination, transcription and translation — occurred in
less than 12 hours.
Next, we generated Cre fusion proteins using the
hormone-binding domain of a mutant mouse estrogen
receptor, ERTM, which fails to bind the naturally 
occurring ligand 17β-estradiol at normal concentrations
but retains relatively high affinity for the synthetic ligand
4-hydroxytamoxifen (4-OHT) [8–10]. Estrogen receptor
fusion proteins are inactive and are probably sequestered
in the cytoplasm, bound to heat shock protein-90, but are
released on binding of ligand (reviewed in [11]). A tran-
sient transfection assay using a cell line containing an inte-
grated single-copy reporter was used to test Cre fusion
proteins with or without a nuclear localisation signal, and
different peptide linkers between the Cre and ERTM
components. Of these, a form lacking a nuclear localisa-
tion signal and containing a short peptide linker displayed
a high level of inducibility with 4-OHT (data not shown).
Similar Cre–ER fusion proteins have been reported by
others [3,5], which can function in a ligand-dependent
manner in adult mice [3,12,13].
The Cre–ERTM cDNA was placed under the regulation of
the Wnt1 enhancer. Three expressing transgenic lines
were tested and the two that expressed at higher levels
gave the best, and essentially identical, results. For
brevity, we only discuss line 10. To determine if recombi-
nation occurred in the absence of ligand, we crossed lines
R170 and Cre–ERTM-10 and stained for β-galactosidase
activity at 11.5 dpc. All embryos determined by geno
typing to be carrying both transgenes showed a staining
pattern that was indistinguishable from embryos carrying
only the reporter, whether pregnant mice were uninjected
or injected with corn oil (carrier; n > 14; Figure 1g). When
the pregnant mice from this intercross were injected
intraperitoneally with 1.0 mg tamoxifen (TM) per day for
four consecutive days (from 7.5 to 10.5 dpc) prior to collec-
tion at 11.5 dpc, a regimen described in [3], strong and
reproducible β-galactosidase staining was obtained in the
Wnt1 pattern in all embryos carrying both transgenes
(n = 17; Figure 1h). However, although most embryos
were viable at 11.5 dpc, pregnancies failed shortly there-
after (n > 4 litters) presumably due to the anti-estrogenic
properties of TM (reviewed in [14]).
To develop an effective dosing strategy over our period of
interest, between 7.5 to 10.5 dpc, we injected different
doses of TM and scored viable pups at term. A single
2.0 mg injection of TM at 8.5 dpc led to a rapid loss of
embryos, whereas two consecutive injections of 1.0 mg at
7.75 and 8.5 dpc, or 8.5 dpc and 9.5 dpc, led to approxi-
mately 50% to 75% lethality at term. A single 1.0 mg injec-
tion was, however, not lethal (n > 4 litters, in each case). 
As 1.0 mg TM appeared to be the highest dose tolerated
without significant lethality, we tested the effectiveness
of a single injection at 7.5, 8.5, 9.5 or 10.5 dpc to activate
the reporter, scoring embryos at 11.5 dpc (Figure 2a–d).
All embryos carrying both transgenes collected from mice
injected at 9.5 dpc (n = 5) or 10.5 dpc (n = 7) showed
extensive β-galactosidase activity throughout the Wnt1
expression domain, comparable to that seen previously in
embryos receiving four consecutive administrations of
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Figure 1
Inducible Cre-mediated recombination in the developing central nervous
system in utero. (a) Practically no β-galactosidase activity was detected
in 11.5 dpc embryos that were transgenic for the Cre reporter alone,
except for weak ventral midbrain staining, which appeared after 48 h, in
all lines tested. Consequently, staining for β-galactosidase activity was
terminated after 24 h in all experiments. (b–d) Representative embryos at
(b,c) 8.5 dpc and (d) 11.5 dpc in which recombination had occurred in
the zygote, resulting in β-galactosidase activity in the Wnt1 expression
pattern; (b,d) are lateral views; (c) is a dorsal view of the embryo in (b)
showing expression in the developing midbrain. (e,f) In embryos that
were transgenic for the Cre reporter and the Cre-expressing transgene,
β-galactosidase activity was detected in the Wnt1 expression pattern at
(e) 8.5 dpc and (f) 11.5 dpc, indicating that Cre-mediated recombination
had occurred in the developing neural tube. (g) In 11.5 dpc embryos
carrying the Cre reporter and the Cre–ERTM-expressing transgene, no
other sites of β-galactosidase activity (compared with the reporter alone)
were detected when pregnant mice were injected with carrier (corn oil)
alone. (h) Injection of tamoxifen, however, induced strong 
β-galactosidase staining in the Wnt1 expression pattern showing that
Cre recombinase activity is inducible. Representative embryos are shown. 
(a) (b)
(c)
(d)
(e) (f)
(g) (h)
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TM. Thus, a single dose of TM induced rapid (within
24 hours) recombination-mediated activation of the
reporter. Injection of 1.0 mg TM at 7.5 dpc reproducibly
gave very limited reporter activation that was restricted to
the midbrain, consistent with the early midbrain-
restricted expression of the Wnt1 enhancer (n = 5). All
numbers refer to embryos carrying both transgenes, all of
which gave very similar results. Activation was also less
efficient at 8.5 dpc (n = 11) and restricted, in the spinal
cord, to more rostral regions. Less efficient recombination
after injection at 7.5 and 8.5 dpc may reflect lower levels
of Cre–ERTM protein, but we note that Wnt1–Cre lines
activate the reporter efficiently by 8.5 dpc. More likely,
the establishment of a chorio-allantoic placental connec-
tion around 9.0 dpc increases the availability of ligand to
the embryo. These results also indicate that induction of
Cre activity is transient. 
To assess whether lower concentrations of TM induce
recombination, we examined reporter activation following
injection of 0.5 mg and 0.1 mg TM at 9.5 dpc. No activa-
tion was observed with a 0.1 mg dose, indicating that this
concentration of TM is below the threshold for activation
of Cre–ERTM (n = 19, data not shown). Injection of 0.5 mg
TM led to a reproducibly reduced frequency of lacZ-
expressing cells (n = 12; Figure 2e). Thus, by lowering the
dose and changing the time of TM injection, it is possible
to modulate the efficiency and spatial distribution of
recombination in target cells. This could be a considerable
advantage in some approaches, allowing the production of
genetic mosaics in which gain or loss of function is
restricted to small populations of cells in an otherwise
wild-type background, a standard approach in genetic
analyses of Drosophila development.
It is thought that TM is converted by the maternal liver
into 4-OHT, which is bound more efficiently by the ER
[14]. Thus, injection of 4-OHT may induce Cre activity
more efficiently; this may, however, be offset by the
longer serum half-life of TM (12 hours, compared with
6 hours for 4-OHT) [15]. Our results indicated that injec-
tion of a range of concentrations of 4-OHT from 0.1 mg to
2.0 mg at 9.5 dpc gave similar results to TM. No recombi-
nation was observed at 0.1 mg; 2.0 mg led to a rapid termi-
nation of pregnancy, and 1.0 mg was significantly better
than 0.5 mg (data not shown). Interestingly, 1.0 mg
4-OHT was not more effective than 1.0 mg TM (n = 3;
compare Figure 2c and 2f). 
These experiments indicated that the most useful
regimen was a single 1.0 mg injection of tamoxifen at
9.5 dpc or later. Analyses of tissue sections indicated that,
following a single 1.0 mg injection of tamoxifen at 9.5 dpc,
recombination had occurred in around 25% of the cells
when compared with the zygotically recombined allele,
which represents 100% recombination (for examples, see
Figure 3). Note that the recombined transgene expressed
lacZ from 8.0 dpc, compared with 9.5 dpc (at the earliest)
for the transgene in which recombination had been
induced by tamoxifen. 
In summary, we have demonstrated that ligand-inducible
recombination can be used to modulate gene activity in
developing mouse embryos. Although the system we
describe is simple and effective, there is clearly room for
improvement. The biggest problem is the high concen-
tration of ligand required, which is necessitated by the fact
that the point mutation that allows preferential binding of
4-OHT rather than 17β-estradiol also decreases the
binding affinity for 4-OHT [13]. Consequently, the dose
of ligand required to activate Cre–ERTM is quite close to
that which interferes with the maintenance of pregnancy.
Potential solutions include screening other ligands for
their ability to induce Cre–ERTM activity or screening for
other ER variants that fail to bind 17β-estradiol efficiently
but retain a high affinity for TM or 4-OHT.
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Temporal analysis of inducible Cre-mediated recombination. One
injection of tamoxifen (1.0 mg) was administered at (a) 7.5 dpc,
(b) 8.5 dpc, (c) 9.5 dpc and (d) 10.5 dpc, and embryos analysed at
11.5 dpc. Representative embryos are shown. At earlier stages (a,b),
some β-galactosidase staining was detected but only in areas where the
transgene was expressed at early stages. Later injections (c,d) led to
strong β-galactosidase staining in the entire Wnt1 pattern. 
(e) Injection of 0.5 mg tamoxifen at 9.5 dpc. (f) Injection of 1.0 mg 4-
OHT at 9.5 dpc was not more efficient than 1.0 mg tamoxifen in
activating the reporter.
Supplementary material
Supplementary materials and methods are published with this paper on
the internet. 
Acknowledgements
We thank Malcolm Parker for pBSK+MERG525 (ERTM), Pierre Vassalli for
pCAGGS-Cre, Klaus Rajewsky for pMC-CRE, Benoit St-Jacques for the
floxed PGKneobpA construct, Retha Newbold for helpful advice on tamox-
ifen administration and our colleagues for their help and comments on the
manuscript. This work was supported by a postdoctoral fellowship from the
Human Frontiers Science Program to P.S.D., a Markey Exploratory
Research Grant to P.S.D. and A.P.M. and grants HD30249 and NS33642
from the NIH to A.P.M.
References
1. Porter A: Controlling your losses: conditional gene silencing in
mammals. Trends Genet 1998, 14:73-79.
2. Metzger D, Clifford J, Chiba H, Chambon P: Conditional site-specific
recombination in mammalian cells using a ligand-dependent
chimeric Cre recombinase. Proc Natl Acad Sci USA 1995,
92:6991-6995.
3. Feil R, Brocard J, Mascrez B, LeMeur M, Metzger D, Chambon P:
Ligand-activated site-specific recombination in mice. Proc Natl
Acad Sci USA 1996, 93:10887-10890.
4. Kellendonk C, Tronche F, Monaghan AP, Angrand PO, Stewart F,
Schutz G: Regulation of Cre recombinase activity by the synthetic
steroid RU 486. Nucleic Acids Res 1996, 24:1404-1411.
5. Zhang Y, Riesterer C, Ayrall AM, Sablitzky F, Littlewood TD, Reth M:
Inducible site-directed recombination in mouse embryonic stem
cells. Nucleic Acids Res 1996, 24:543-548.
6. Echelard Y, Vassileva G, McMahon AP: Cis-acting regulatory
sequences governing Wnt-1 expression in the developing mouse
CNS. Development 1994, 120:2213-2224.
7. Lee SM, Danielian PS, Fritzsch B, McMahon AP: Evidence that FGF8
signalling from the midbrain-hindbrain junction regulates growth
and polarity in the developing midbrain. Development 1997,
124:959-969.
8. Fawell SE, Lees JA, White R, Parker MG: Characterization and
colocalization of steroid binding and dimerization activities in the
mouse estrogen receptor. Cell 1990, 60:953-962.
9. Danielian PS, White R, Hoare SA, Fawell SE, Parker MG:
Identification of residues in the estrogen receptor that confer
differential sensitivity to estrogen and hydroxytamoxifen. Mol
Endocrinol 1993, 7:232-240.
10. Littlewood TD, Hancock DC, Danielian PS, Parker MG, Evan GI: A
modified oestrogen receptor ligand-binding domain as an
improved switch for the regulation of heterologous proteins.
Nucleic Acids Res 1995, 23:1686-1690.
11. Mattioni T, Louvion JF, Picard D: Regulation of protein activities by
fusion to steroid binding domains. Methods Cell Biol 1994,
43:335-352.
12. Brocard J, Warot X, Wendling O, Messaddeq N, Vonesch JL,
Chambon P, Metzger D: Spatio-temporally controlled site-specific
somatic mutagenesis in the mouse. Proc Natl Acad Sci USA 1997,
94:14559-14563.
13. Schwenk F, Kuhn R, Angrand PO, Rajewsky K, Stewart AF:
Temporally and spatially regulated somatic mutagenesis in mice.
Nucleic Acids Res 1998, 26:1427-1432.
14. Jordan VC, Murphy CS: Endocrine pharmacology of antiestrogens
as antitumor agents. Endocr Rev 1990, 11:578-610.
15. Robinson SP, Langan-Fahey SM, Johnson DA, Jordan VC:
Metabolites, pharmacodynamics, and pharmacokinetics of
tamoxifen in rats and mice compared to the breast cancer patient.
Drug Metab Dispos 1991, 19:36-43.
1326 Current Biology, Vol 8 No 24
Figure 3
(b) (d) (e) (f)(a) (c)dmb dmb
Current Biology   
jj
Embryo sections showing lacZ expression from the Cre reporter
following ligand-induced recombination. (a) Coronal section through
the brain of a representative 11.5 dpc embryo — carrying the zygotically
recombined Cre reporter — stained for β-galactosidase activity.
(b) Similar section of a representative 11.5 dpc embryo in which
recombination of the reporter was induced by injection of 1.0 mg
tamoxifen at 9.5 dpc. (c) High-power view of the dorsal midbrain in (a).
(d) High-power view of the dorsal midbrain in (b). (e) Section through
the spinal cord at the level of the dorsal root ganglion and forelimb
from a 11.5 dpc embryo carrying the zygotically recombined Cre
reporter. Note that migrating neural crest cells stain for
β-galactosidase activity. (f) Section at the same level as in (e) from an
11.5 dpc embryo in which recombination of the reporter had been
induced by injection of 1.0 mg tamoxifen at 9.5 dpc. All sections are
6 µm; dmb, dorsal midbrain; j, midbrain–hindbrain junction.
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Construction of transgenes
A reporter construct for Cre recombinase activity in vivo was derived
from a Wnt1-enhancer-based expression construct pWEXPZ2 [S1]. A
PGKneobpA cassette [S2] which had been flanked with loxP sequences
(Benoit St-Jacques and A.P.M., unpublished) was subcloned as a
SalI–BamHI fragment into pSL1180 (Pharmacia) with a BglII–XbaI frag-
ment containing the Escherichia coli lacZ cDNA. This placed the floxed
PGKneobpA cassette upstream of the lacZ cDNA. A SwaI–BamHI frag-
ment containing this array was subcloned into pWEXPZ2 from which the
lacZ tag had been removed. This placed the array between the Wnt1
promoter and Wnt1 enhancer in pWEXPZ2 (Figure S1).
To generate Cre–ERTM, a ClaI–EcoRI fragment from pCAGGS–Cre
[S3], containing the cDNA encoding Cre recombinase, was subcloned
into Bluescript (Stratagene) and modified using PCR with a KS primer
and the primer 5′-TCGCGGATCCCCATCTTCCAGCAGGCGCACC-
3′ to generate a BamHI site at the last codon of the Cre cDNA. Follow-
ing DNA sequence verification, this PCR product was subcloned back
into pCAGGS–Cre together with a BamHI–EcoRI fragment from
pBSK+MERG525 containing the cDNA encoding the hormone-
binding domain (amino acids 281–599) of the mutant mouse estrogen
receptor, ERTM [S4]. Subsequently, a ClaI–EcoRI fragment was
removed from this plasmid in order to insert a pair of annealed oligonu-
cleotides (5′-GATCAGGCTGGTGCCATGGGC-3′; 5′-GATCGCC-
CATGGCACCAGCCT-3′) at the BamHI site, introducing the amino
acids QAGAMG between the two components of the fusion protein.
This modified ClaI–EcoRI fragment was then subcloned into Bluescript
(Stratagene) with a XhoI–ClaI fragment from pBS185 (GIBCO BRL)
containing part of the Cre cDNA to regenerate the complete Cre–ERTM
cDNA. From this plasmid an ApaI–EcoRI fragment was subcloned into
pWEXPZ2 from which the lacZ tag had been removed. This placed the
cDNA encoding Cre–ERTM between the Wnt1 promoter and Wnt1
enhancer in pWEXPZ2 (Figure S1). In initial tests of Cre–ERTM fusion
proteins, a Cre cDNA containing sequence encoding a nuclear locali-
sation signal was derived from pMC–Cre. The Cre-expressing trans-
gene will be described elsewhere. 
Generation and genotyping of transgenic mice
For electroporation into ES cells, the Cre recombinase reporter con-
struct was digested with SalI and separated from the plasmid back-
bone by gel electrophoresis and recovered by electroelution as
described [S1]. Electroporation of R1 ES cells [S5] with the Cre
recombinase reporter construct and selection for cells in which inte-
gration had occurred with G418 (GIBCO BRL) was performed
essentially as described [S6]. ES cell clones were screened for inte-
gration events by Southern analysis of genomic DNA digested with
SphI using a radiolabelled probe generated from a 400 bp XhoI–SphI
genomic fragment from Wnt1 essentially as described [S7]. The
endogenous Wnt1 gene was detected as a 5 kb band whilst the
transgene was detected as a 4.35 kb band. Of 134 clones analysed,
23 clones appeared to contain a single integrated copy of the trans-
gene; 42 two copies; 33 multiple copies; 18 rearranged copies and
18 no copies. As Wnt1 is not expressed in ES cells [S8], chimeric
males were generated directly from six of the clones judged to
contain a single copy of the transgene by injection into C57BL/6J
recipient blastocysts to generate chimeras [S9]. Chimeric males were
intercrossed to C57BL/6J females and agouti offspring were initially
genotyped by Southern analysis of genomic DNA using the probe
described above. Subsequently Cre recombinase reporter transgenic
offspring were genotyped using a PCR-based assay using oligonu-
cleotides identical to sequence at the 3′ end of the PGKneobpA cas-
sette (5′-GCAGGCATGCTGGGGATGCGG-3′) and one identical to
the 5′ end of the lacZ cDNA (5′-GCGATTAAGTTGGGTAACGC-3′).
Amplification was achieved using 40 cycles of 30 sec at 94°C,
30 sec at 55°C and 30 sec at 72°C. 
Removal of the PGKneobpA cassette by Cre-mediated recombina-
tion in zygotes was achieved essentially as described [S3]. Gel-puri-
fied supercoiled pCAGGS–Cre plasmid was injected at 0.5 ng/µl
into the pronucleus of zygotes from Cre reporter × B6CBAF1
crosses and surviving two-cell embryos were transferred into
pseudopregnant SWB recipients. These offspring were initially geno-
typed by Southern analysis of genomic DNA digested with BglII
using the probe described above and subsequently by a PCR-based
assay using oligonucleotides identical to sequence in the Wnt1 pro-
moter (5′-TAAGAGGCCTATAAGAGGCGG-3′) and that identical to
the 5′ end of the lacZ cDNA described above using the same reac-
tion conditions. No PCR reaction products were detected using
these oligonucleotides and the unrecombined reporter allele. Loss of
the PGKneobpA cassette was additionally assessed by PCR using
the strategy described for the unrecombined reporter. Of the six
lines generated three (9, 44 and 170) were judged to contain a func-
tional Cre reporter transgene. The remaining three clones contained
transgenes which failed in this assay and PCR analysis indicated
that this was due to the fact that the Wnt1 promoter had been lost
from the transgene.
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Figure S1
Wnt1-enhancer-based Cre recombinase reporter and Cre expression
transgenes. (a) Schematic diagram of the Cre reporter transgene. The
presence of the loxP-flanked PGKneobpA cassette (neo) prevents
translation of the lacZ cDNA (grey box) until it is deleted by Cre-
mediated recombination. The pink and blue boxes represent,
respectively, translated and untranslated parts of Wnt1 exons in the
pWEXPZ2 transgene vector. (b) Schematic diagram of transgene
expressing Cre; details as in (a). (c) Schematic diagram of transgene
expressing the tamoxifen-inducible Cre–ERTM; details as in (a).
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Generation of transgenic mice by pronuclear injection of transgene
DNA was performed essentially as described [S1,S10]. For the
Wnt1–Cre construct of the fifteen founders generated, eight transmit-
ted Wnt1–Cre through the germ line and six expressed the transgene
in the Wnt1 pattern. For the Cre–ERTM construct, thirteen transgenic
founder lines were generated and five out of six male founders transmit-
ted an expressing transgene as judged by whole mount in situ hybridis-
ation. Mice carrying the Cre–ERTM transgene were initially identified by
Southern analysis of genomic DNA digested with BamHI using radiola-
belled probes generated from a 600 bp BamHI fragment of the Cre
cDNA. Transgenic Cre–ERTM offspring were subsequently genotyped
using a PCR-based assay similar to that described above but with
oligonucleotides identical to sequence in the 3′ of the Cre cDNA (5′-
AACCTGGATAGTGAAACAGGGGC-3′) and sequence in the 5′ of
the mouse estrogen receptor hormone-binding domain cDNA (5′-TTC-
CATGGAGCGAACGACGAGACC-3′). All embryos were numbered
by limb removal during dissection and yolk sacs collected for genotyp-
ing by PCR as previously described [S10]. 
Whole-mount β-galactosidase staining 
Analysis of β-galactosidase activity in whole embryos and subsequent
histological analysis was performed as described [S10]. 
Ligand administration
Tamoxifen (Sigma) or 4-hydroxytamoxifen (RBI) were dissolved in warm
corn oil (Sigma) at the desired concentration and stored at 4°C.
Intraperitnoeal injections of 0.1 ml were given as indicated. Corn oil
was injected as a control. 
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